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Abstract Prostate cancer is a commonly diagnosed cancer
in men and a leading cause of cancer deaths. Whilst the
underlying mechanisms leading to prostate cancer are still
to be determined, it is evident that both genetic and
epigenetic changes contribute to the development and
progression of this disease. Epigenetic changes involving
DNA hypo- and hypermethylation, altered histone modifi-
cations and more recently changes in microRNA expression
have been detected at a range of genes associated with
prostate cancer. Furthermore, there is evidence that particular
epigenetic changes are associated with different stages of the
disease. Whilst early detection can lead to effective treatment,
and androgen deprivation therapy has a high response rate,
many tumours develop towards hormone-refractory prostate
cancer, for which there is no successful treatment. Reliable
markers for early detection and more effective treatment
strategies are, therefore, needed. Consequently, there is a
considerable interest in the potential of epigenetic changes as
markers or targets for therapy in prostate cancer. Epigenetic
modifiers that demethylate DNA and inhibit histone deacety-
lases have recently been explored to reactivate silenced gene
expression in cancer. However, further understanding of the
mechanisms and the effects of chromatin modulation in
prostate cancer are required. In this review, we examine the
current literature on epigenetic changes associated with
prostate cancer and discuss the potential use of epigenetic
modifiers for treatment of this disease.
Keywords Prostate cancer.Epigenetics.DNA
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Introduction
Prostate cancer is the most commonly diagnosed cancer for
men living in developed countries (other than non-
melanoma skin cancer). According to Cancer Research
UK, an estimated 913,000 men worldwide were diagnosed
in developed countries in 2008. According to the US
National Cancer Institute, it was estimated that almost
217,730 men would be diagnosed in the USA alone in 2010
and more than 32,050 would die as a direct result of the
disease. The use of prostate-specific antigen (PSA) as a
screening tool has allowed the detection of prostate cancer
in the early stages whilst it is still locally confined. Whilst
more than 70% of diagnosed cases now survive beyond
5 years, this cancer is still associated with significant
mortality and morbidity. Metastatic prostate tumours are
responsible for the majority of deaths associated with this
cancer. The most frequent site of prostate cancer metastasis
is to bone; over 80% of men who die of prostate cancer
have metastatic boney lesions (Bubendorf et al. 2000). In
terms of current treatments for prostate cancer, we are still
unable to identify with certainty those tumours requiring
aggressive and immediate intervention (associated with
considerablemorbidity)andthosewherea“watchful-waiting”
approach may be more appropriate. Thus, identification of
markers predicting tumour behaviour has become of intense
interesttoresearchersworkingtodiscovernewprognosticand
diagnostic markers and new targets for treatment.
Prostatic intraepithelial neoplasia (PIN) and, in particular,
high-grade PIN has been identified as precancerous lesions
most likely leading to prostatic carcinoma. On the prostate
morphological spectrum, PIN refers to precancerous lesions
involving cell proliferation within prostatic ducts, ductules
and acini (De Marzo et al. 2004). PIN is believed to pre-date
carcinoma by 10 or more years. High-grade PIN is
considered clinically significant as men with high-grade
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prostate cancer (Lee et al. 2011). A second morphological
abnormality termed atypical small acinar proliferation has
also been associated with increased risk of diagnosis with
prostate cancer in subsequent biopsies. Prostate tumours are
most commonly graded using the Gleason score, determined
by the histological characteristics of the glandular architecture
within the tumour.
It is clear that epigenetic changes within a cell play a
significant role in the development and progression of
cancer (Esteller 2008; Jones and Baylin 2007) and, as in
most other human cancers, prostate cancer development
and progression appears to involve an interplay between
both genetic and epigenetic changes. There is now
considerable evidence that changes in gene expression
which involve epigenetic alterations may be an important
factor in prostate cancer progression, and development of
panels of epigenetically modified genes as markers of
disease progression is of considerable topical interest.
Epigenetic mechanisms
Epigenetic alterations are heritable changes in gene
expression that occur without changes in DNA sequence,
with the broadest definition including all factors other
than DNA sequence changes that heritably influence
gene expression (Berger et al. 2009). Whilst the best
described of these mechanisms is DNA methylation, other
epigenetic mechanisms include physical and chemical
changes to chromatin and regulation of gene expression
by microRNAs (miRNAs).
DNA methylation plays an important role in DNA repair,
recombination and replication, as well as regulating gene
activity (see Fig. 1). DNA methylation involves the addition
of a methyl group to the 5′-carbon of cytosine in CpG
dinucleotide sequences, catalysed by a family DNA methyl-
transferases (DNMTs). CpG-rich regions, known as CpG
islands are commonly found associated with the 5′-region of
vertebrate genes (Gardiner-Garden and Frommer 1987)a n d
are generally protected from methylation (Bird 2002). For
many years, CpG islands have been implicated in gene
regulation with their methylation strongly correlated with
gene silencing (Illingworth and Bird 2009). DNA methyla-
tion can regulate gene activity via two mechanisms. Firstly,
methylation of CpG dinucleotides within transcription factor
binding sites can inhibit transcription factor binding and,
therefore, directly influence gene activity (Hark et al. 2000).
Secondly, methylated CpG dinucleotides act as binding sites
for methyl CpG binding proteins, which are associated with
other factors such as histone deacetylases, involved in
establishing repressive chromatin structures (Jones et al.
1998; Nan et al. 1998).
Changes in DNA methylation patterns have been linked
with cancer for many years now (Jones and Baylin 2007).
However, the methylation changes are complex, with both
hypomethylation and hypermethylation occurring in cancer
cells. Aberrant DNA hypermethylation occurs when there is
a gain of DNA methylation at regions that are normally
unmethylated and when this occurs at gene promoters can
lead to gene inactivation. Localised hypermethylation of
gene promoters has been reported in virtually all types of
cancers, including prostate cancer. On the other hand, DNA
hypomethylation is the demethylation of normally methyl-
ated DNA and can lead to chromosomal instability and
activation of proto-oncogenes (Dunn 2003; Eden et al.
2003; Sharma et al. 2010). Both global and gene-specific
hypomethylation events have also been implicated in
prostate cancer.
Whilst alterations in DNA methylation have long been
linked to cancer, there is also mounting evidence that
other epigenetic changes, such as changes to chromatin
composition or structure, contribute to cancer. Within the
eukaryotic nucleus, DNA is assembled into chromatin,
the basic unit of which is the nucleosome. Nucleosomes
are composed of approximately 147 base pairs of DNA
wrapped around an octamer of core histone proteins,
containing two each of histones H2A, H2B, H3 and H4
(Kornberg and Lorch 1999). The N termini of the core
histones protrude from the nucleosome and are subjected
to a range of covalent modifications, catalysed by various
histone-modifying enzymes. At least ten different histone
modifications have now been reported, including acetyla-
tion, methylation, phosphorylation and ubiquitination
(Kouzarides 2007;G a r d n e re ta l .2011). Each of these
modifications affects the chromatin structure and function
in a different way by either disrupting chromatin contacts
or affecting the recruitment of other proteins to the
chromatin (Kouzarides 2007). Acetylation of lysine resi-
dues in histone H3 and H4 (H3Ac and H4Ac) is in general
associated with transcriptional activity, whereas histone
methylation is associated with transcriptional activation or
repression depending on the site of modification and the
number of methyl groups added (see Fig. 1). For example,
histone H3 lysine 4 (H3K4) methylation is generally
associated with transcriptional activation, whereas histone
H3lysine9(H3K9)andhistoneH3lysine27(H3K27)di-and
tri-methylation is generally associated with transcriptional
repression (Kouzarides 2007). As with DNA methylation,
there is an increasing body of evidence that changes in
histone modifications due to aberrant activity or mis-
targeting of chromatin-modifying enzymes is involved in
carcinogenesis (Hake et al. 2004).
More recently, miRNAs have been identified as impor-
tant regulators of gene expression. miRNAs are endogenous
small non-coding, single-stranded RNAs, 18–24 bases
152 Clin Epigenet (2011) 2:151–169long, which regulate gene expression by affecting the
stability or the translation efficiency of target mRNAs
(Pang et al. 2010). The miRNA binds to complementary
sequences within the 3′ mRNA tails, although usually only
with partial base pair complementarity. When miRNAs bind
to mRNA with partial complementarity, they function as
translational repressors whereas perfect complementarity
induces degradation of the target mRNA (He and Hannon
2004; Porkka et al. 2007). Recent studies have found that
aberrations in miRNA expression are associated with
various human cancers including prostate cancer. About
half of the known miRNA genes are located at cancer-
related genomic regions (Calin et al. 2004), and in cancer,
miRNAs can function as either oncogenes or tumour
suppressor genes (Hayashita et al. 2005;H ee ta l .2005).
One miRNA can target hundreds of mRNAs and, therefore,
alterations in a single miRNA can have dramatic effects on
cell biology. Our understanding of the function and
regulatory mechanisms of miRNAs has expanded enor-
mously over recent years; however, we still have limited
capacity to identify targets of miRNAs and have much to
learn about their involvement in cellular processes and
disease.
Epigenetic alterations in prostate cancer progression
DNA hypomethylation
There is considerable evidence that changes in methylation
patterns occur in prostate cancer with DNA hypomethyla-
tion in tumour samples first documented more than 20 years
ago. In 1987, Bedford and van Helden analysed DNA 5′-
methylcytosine content in human prostate samples and
reported a correlation between global hypomethylation and
development of benign prostatic hyperplasia (BPH) and
metastatic tumours (Bedford and van Helden 1987).
ComparisonofDNAmethylationlevelsintumourandnormal
prostate tissue by immunohistochemistry similarly detected
global hypomethylation in prostate cancer (Brothman et al.
2005). In keeping with this, Santourlidis et al. (1999)
examined methylation of LINE-1 repetitive sequences in
prostate adenocarcinomas and found that LINE-1 methyla-
tion tended to decrease with tumour stage. A further study
analysing tumour samples similarly demonstrated an associ-
ation between DNA hypomethylation, tumour state and
metastasis, with extensive hypomethylation of LINE-1
observed in 64% of cases with lymph node or distant
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Fig. 1 A model depicting epigenetic modifications associated with different transcriptional states and some of the inhibitors that target epigenetic
modifiers and, therefore, influence transcriptional activitymetastases but only in 21% of cases without detectable
metastases (Schulz et al. 2002). All cases of hormone-
refractory locally recurrent tumours displayed extensive
LINE-1 hypomethylation. The study by Schulz et al.
(2002) also found a strong association between LINE-1
DNA hypomethylation and chromosomal alterations, in
support of the notion that DNA hypomethylation increases
genomic instability (Schulz et al. 2002). Most prostate
cancer samples with prominent DNA hypomethylation also
exhibited a large number of chromosomal alterations and
vice versa. These findings were supported by a further study
which found increased prevalence of LINE-1 hypomethyla-
tion in later-stage prostate cancers and lymph-node-positive
prostate cancers (Florl et al. 2004), in contrast to gene-
specific hypermethylation events which did not correlate
with tumour stage, being present in both early and late-stage
prostate cancer. These data, therefore, suggest that hypome-
thylation is a later event in prostate cancer progression
compared with gene-specific hypermethylation. Consistent
with this, a recent study examined LINE-1 methylation in
primary prostate cancers compared with normal prostate
tissues and found a significantly higher level of LINE-1
hypomethylation in metastatic prostate cancer tissues, sug-
gesting that global hypomethylation occurs late in prostate
cancer progression, particularly at the metastatic disease
stage (Y egnasubramanian et al. 2008).
Whilst global DNA hypomethylation can contribute to
cancer by promoting genomic instability, the hypomethyla-
tion of individual gene promoters can also contribute to
cancer development and progression by directing aberrant
gene expression. Hypomethylation of a number of genes
has been linked to prostate cancer. For example, a study by
Yegnasubramanian et al. (2008), found that CpG islands
associated with a class of cancer testis antigen genes were
hypomethylated in prostate cancer, correlating with their
overexpression in primary prostate cancers, and more so in
metastatic prostate cancer. Similarly, hypomethylation of
the promoter of the heparanase gene has been reported in
prostate cancer, compared with BPH (Ogishima et al.
2005). This correlates with increased mRNA expression
of the heparanase gene, which is associated with tumour
invasion and metastasis (Vlodavsky et al. 1988; Hulett et al.
1999). Further, upregulation of urokinase expression in
invasive prostate cancer cell lines correlates with hypome-
thylation of the promoter (Pakneshan et al. 2003). Upregu-
lation of cytochrome P450 1B1 (CYP1B1) mRNA and
protein levels in prostate cancer compared with BPH tissue
was also found to correlate with hypomethylation of the
regulatory regions of this gene (Tokizane et al. 2005). Other
genes such as wingless-related MMTV integration site 5A
(WNT5A), S100 calcium-binding protein P and cysteine-
rich protein 1 were also found to be hypomethylated in
primary prostate cancer tissues. These genes are similarly
associated with tumourigenesis and metastasis (Dissanayake
et al. 2007;W a n ge ta l .2006). Further investigation of the
WNT5A gene revealed three CpG sites in the promoter
region which were consistently methylated in a normal
prostate cell line and normal prostate tissues but not in a
prostate cancer cell line and primary prostate cancer tissues
(Wang et al. 2007). Therefore, hypomethylation and conse-
quent upregulation of genes involved in metastasis and cell
invasion may be an important factor in prostate cancer
progression. In support of this, treatment of the PC3
prostate cancer cell line with reagents that prevent DNA
hypomethylation has an inhibitory effect on cell invasion in
vitro and tumour growth in vivo (Shukeir et al. 2006).
DNA hypermethylation
DNA hypermethylation is the most commonly reported
epigenetic alteration observed in prostate cancer. Many
genes have been identified as aberrantly hypermethylated in
prostate cancer and these genes include tumour suppressor
genes, DNA damage repair genes, hormonal response genes
and genes involved in cell cycle control, tumour cell
invasion and metastasis (Phé et al. 2010). Hypermethylation
of DNA can lead to inappropriate gene silencing, disrupting
gene function and, thus, contributing to tumour initiation,
progression and metastasis (Li et al. 2004). This review
highlights some of the best described and most frequently
hypermethylated genes in prostate cancer.
The most frequently reported hypermethylated gene in
prostate cancer is the π-class glutathione-S-transferase
(GSTP1) gene. GSTP1 is an enzyme involved in the
metabolism, detoxification and elimination of reactive
chemical compounds and in this way protects cells from
DNA damage and cancer initiation (Lee 2007). Hyper-
methylation of the GSTP1 gene in prostate cancer was first
reported by Lee et al. (1994) who found hypermethylation
of the gene in all 20 human prostate cancer tissue samples
examined, but not in normal tissues or BPH. Following
this, GSTP1 gene expression was analysed in 60 high-
grade PIN samples, with all samples showing a loss of
GSTP1 gene expression (Brooks et al. 1998). Further
investigation found that this loss of GSTP1 expression was
due to hypermethylation of the gene promoter. A large
number of studies have now reported GSTP1 hypermethy-
lation in prostate cancer samples, with methylation detected
in up to 90% of samples, suggesting GSTP1 hyper-
methylation is a common epigenetic alteration in prostate
cancer (Goessl et al. 2001; Chu et al. 2002; Jeronimo et al.
2002; Harden et al. 2003; Nakayama et al. 2003; Bastian et
al. 2004).
Promoter hypermethylation of genes involved in tumour
invasion has also been observed in prostate cancer. The
maintenance of the normal cell architecture is regulated by
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gene expression is associated with the transition from
adenoma to carcinoma and the acquisition of metastatic
potential (Perl et al. 1998). CDH1 hypermethylation was
observed in prostate cancer cell lines and treatment with the
demethylating agent, 5-aza-2′-deoxycytidine restored
CDH1 mRNA and protein expression in the cell lines,
suggesting that promoter hypermethylation was responsible
for CDH1 silencing in these cells (Graff et al. 1995).
Furthermore, Kallakury et al. (2001) reported that the
CDH1 gene promoter was methylated in eight out of ten
prostate cancer tissues examined. Interestingly, the degree
of CDH1 promoter methylation correlated with the patho-
logical stage of the prostate tumour tissues, with CDH1
promoter methylation occurring in 30% of low-grade
prostate cancer tissues, but increasing to 70% in high-
grade tumours (Li et al. 2001). These results suggest that
methylation of the CDH1 promoter is associated with
prostate tumour progression.
CD44, which is a cell surface glycoprotein involved in
cell matrix adhesion and signal transduction is also silenced
in prostate cancer by methylation of the gene promoter. Lou
et al. (1999) examined methylation levels of the CD44 gene
in 84 matched normal and prostate cancer samples and
found hypermethylation of CD44 in 31 out of 40 of the
primary prostate cancer samples. Further investigation by
V erkaik et al. (1999) showed that in CD44-negative prostate
cancer cell lines (LNCaP and PC346C) the CD44 promoter
was hypermethylated compared with CD44-positive prostate
cancer cell lines (Du145, PC3 and TSU). A further study of
CD44 silencing was conducted on human tissue samples and
demonstrated that nine out of 11 lymph node metastases of
prostate cancer displayed CD44 gene promoter methylation.
These data, therefore, suggest that hypermethylation of the
CD44 promoter resulting in downregulation of CD44 gene
expression may be involved in prostate cancer progression
and metastasis (V erkaik et al. 2000).
DNA methylation is also involved in regulation of the
androgen receptor (AR). AR is activated by androgen,
which plays a critical role in the development, growth and
maintenance of the prostate (Jenster 1999). In the initial
stages, prostate cancer is androgen dependent, but eventu-
ally becomes androgen independent, due to the loss of AR
expression (Jarrard et al. 1998; Tekur et al. 2001; Takahashi
et al. 2002; Suzuki et al. 2003). Data from a number of
studies suggest that this loss of AR expression is at least
partly due to hypermethylation of the AR gene promoter.
Jarrard et al. (1998) found AR promoter hypermethylation
in AR-negative prostate cancer cell lines (DU145, DuPro,
TSU-PR1 and PPC1) whereas the promoter was unmethy-
lated in AR-positive cell lines (LNCaP and PC3). Expression
of the AR gene was restored in the AR-negative cell lines by
treatment withthedemethylatingagent5-aza-2′deoxycitidine,
suggesting that promoter methylation was responsible for AR
genesilencingintheAR-negativecelllines.Further,Suzukiet
al. (2003) reported that promoter hypermethylation of AR
leading to loss of AR expression occurs in 30% of hormone-
refractory prostate cancers, suggesting that DNA hyper-
methylation contributes to loss of AR expression in at least
some prostate cancers.
The silencing of cell cycle regulation genes by DNA
hypermethylation has also been observed in prostate cancer.
The Ras-associated domain family 1A gene (RASSF1A) is
highly methylated in several human cancers, including
prostate cancer (Liu et al. 2002; Kang et al. 2004; Pfeifer
and Dammann 2005; Dammann et al. 2005; Aitchison et al.
2007; Hesson et al. 2007). Liu et al. (2002) examined
methylation of the RASSF1A promoter in primary prostate
tumours and reported methylation of the RASSF1A
promoter in over 70% of the tumours. Further investigation
found a correlation between the frequency of methylation
and the Gleason score of the tumour, with highly aggressive
tumours displaying more frequent DNA methylation com-
pared with less aggressive tumours. Similarly, Kang et al.
(2004) reported methylation of a number of genes,
including RASSF1A in prostate cancer and PIN samples,
with more frequent methylation correlating with higher
PSA levels and Gleason score.
Silencing of tumour suppressor genes by DNA methyl-
ation is also often observed in prostate cancer. DNA
hypermethylation of the adenomatous polyposis coli
(APC) gene in prostate cancer individuals was observed
in a study by Rosenbaum et al. (2005), which examined
promoter methylation of a number of genes. Hypermethy-
lation of APC alone, and hypermethylation of APC and the
cell cycle regulation gene cyclin D2 in combination were
found to be significant predictors of prostate cancer
progression. In keeping with this, Henrique et al. (2007)
analysed a small panel of gene promoters in prostate biopsy
samples and similarly found that hypermethylation of APC
is an independent predictor of poor prognosis in prostate
cancer. Subsequent studies have similarly found APC
hypermethylation to be a predictor of prostate cancer
progression (Liu et al. 2011b; Richiardi et al. 2009).
Histone modifications
Compared with DNA methylation the involvement of
histone modifications in prostate cancer is relatively poorly
understood, even though these two epigenetic mechanisms
are closely related (Sharma et al. 2010). However, some
data relating particular histone modifications to prostate
cancer have emerged in recent years. Seligson et al. (2005)
analysed a range of histone modifications by immunohis-
tochemistry including acetylated histone H3 lysine 9,
acetylated histone H3 lysine 18 (H3K18Ac), H4K12Ac,
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H3 lysine 4 (H3K4me2) in 183 primary prostate cancer
tissue samples. In the individuals with low-grade tumours,
the study found two subgroups with different risks of
tumour recurrence based on the presence of similar
combinations of global histone modifications. Individuals
with a lower risk of tumour recurrence were those who
were above the 60th percentile staining for H3K4me2 or
above the 35th percentile staining for H3K18Ac and
H3K4me2. However, these histone modification patterns
did not correlate with the Gleason score. In contrast, a more
recent study of primary and metastatic prostate cancer
samples found that high global levels of H3K18Ac and
H3K4me2 correlated with a threefold increased risk of
prostate cancer recurrence (Bianco-Miotto et al. 2010). A
further study showed that global levels of H3K4me1,
H3K9me2, H3K9me3, H3Ac and H4Ac were significantly
reduced in prostate cancer compared with BPH and normal
prostate tissue (Ellinger et al. 2010), with H3Ac and
H3K9me2 in particular discriminating between the malignant
and non-malignant samples. They also found that individuals
with high H3K4me1 levels were more likely to experience
recurrence of the prostate cancer and thus suggested that
analysis of H3K4me1 may provide predictive information
regarding likelihood of tumour recurrence.
In addition to the studies outlined above that have
documented changes in histone modifications associated
with prostate cancer, there is accumulating evidence that
expression of histone-modifying enzymes is altered in
prostate cancer. Bianco-Miotto et al. (2010) identified a
candidate gene signature consisting of six genes encoding
epigenetic modifiers, including both DNA methyltrans-
ferases and histone methyltransferases (HMTs) that was
associated with prostate cancer progression. In addition, a
number of studies have documented alterations in the HMT
EZH2, which is responsible for the repressive H3K27me3
modification, in prostate cancer. EZH2 is upregulated in
hormone-refractory metastatic prostate cancer (V arambally
et al. 2002). Overexpression of EZH2 in prostate cancer cell
lines increases the invasive characteristics of the cells,
whilst knockdown of EZH2 decreases the proliferative
capacity of the cells, and more so in hormone-independent
cell lines (V arambally et al. 2002; Karanikolas et al. 2010).
Furthermore, microarray analysis of metastatic prostate
cancer tissue identified a group of EZH2 repressed genes
that were associated with prostate cancer progression (Y u et
al. 2007).
A number of studies have also implicated lysine-specific
demethylase 1 (LSD1) in prostate cancer. LSD1 was
originally identified as a H3K4 demethylating enzyme
(HDM). This enzyme was thought to function as a
transcriptional co-repressor by reversing the H3K4me
modifications associated with transcriptional activation
(Shi et al. 2004). However, genome-wide studies of LSD1
homologues in yeast suggest that these enzymes can act as
both co-activators and co-repressors by targeting H3K4 or
H3K9, respectively (Opel et al. 2007). In keeping with this,
LSD1 has been demonstrated to form ligand-dependent,
chromatin-associated complexes with AR, stimulating AR-
dependent transcription (Metzger et al. 2005). In this case,
LSD1 acts by demethylating histone H3K9, thus activating
AR target genes by removing repressive H3K9me modifica-
tions. This study found that LSD1 and AR were co-localised
inbothnormalprostateandprostatecancer.Afurtherstudyby
Kahl et al. (2006) correlated the expression patterns of AR,
LSD1 and the AR co-activator FHL2 (four and a half LIM-
domain protein 2) with Gleason score, Gleason grade and
p53 expression in 153 prostate tumour samples with relapse
after radical prostatectomy. The study found that increased
LSD1, nuclear expression of FHL2, high Gleason score and
grade and high levels of p53 were strongly associated with
relapse during follow-up. In addition, upregulation of both
LSD1 mRNA and protein levels was associated with high
risk of relapse. Whilst LSD1 demethylates H3K9me1 and
H3K9me2, a further study found that the Jumonji C domain
containing protein JMJD2C can demethylate H3K9me3
(Wissmann et al. 2007). JMJD2C associates with AR and
LSD1 in prostate cells, and this complex acts to demethylate
H3K9me3 and increase AR-dependent gene transcription. A
second Jumonji protein, JHDM2A, which also demethylates
H3K9me1/2 has similarly been found to stimulate transcrip-
tion of AR dependent genes (Y amane et al. 2006).
Furthermore, Gaughan et al. (2011)s h o w e dt h a tA Ri n t e r a c t s
with and is methylated by the HMT enzyme SET9. SET9
was originally identified as an enzyme responsible for
catalysing the activating H3K4me1 modification, and,
therefore, was associated with transcriptional activation
(Nishioka et al. 2002). However, Gaughan et al. (2011)
found that by methylating AR SET9 increased the transcrip-
tional activation of AR itself. In doing so, SET9 was found
to have pro-proliferative and anti-apoptotic activity in the
AR-dependent LNCaP prostate cancer cell line.
Whilst the studies outlined above have highlighted
differences in histone modifications and histone modifiers
correlating with prostate cancer stage or recurrence, it
should be noted that many of these studies have described
global changes and further studies are, therefore, needed to
investigate how these global changes relate to gene-specific
loci, particularly at genes that have already been implicated
in prostate cancer.
miRNA regulation
To date, there have been more than 50 miRNAs found to be
deregulated in prostate cancer using sensitive miRNA array
studies on primary tumour samples, normal prostate
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Tang et al. 2011; Wach et al. 2011). A miRNA expression
profiling study using six prostate cancer cell lines (PC3,
DU145, LNCaP , 22Rv1, VCaP and LAPC4), nine prostate
xenograft samples and 12 clinical prostate tissue samples
revealed a miRNA signature of prostate cancer (Porkka et
al. 2007). A total of 51 miRNAs were differentially
expressed in benign tumours and carcinoma tumours, of
which 37 miRNAs were downregulated whilst 14 miRNAs
were upregulated. Based on miRNA expression, the authors
were able to accurately separate the carcinomas from the
BPH samples and also classify the tumours according to
their androgen dependence. This suggests that androgens
might regulate, or be regulated by, some miRNAs. A further
study investigating both miRNA and mRNA profiles in
prostate cancer, similarly found evidence for androgen
regulation of miRNAs (Ambs et al. 2008). This study
reported deregulation of both miRNAs and miRNA
processing pathways in prostate cancer as well as demon-
strating regulation of a set of cancer-associated genes by
miRNAs. Similarly, analysis of miRNA profiles in androgen-
dependent and androgen-independent cell lines by next
generation sequencing revealed a cohort of differentially
expressedmiRNAs,manyofwhichtargetcellcommunication
and signal transduction pathways (Xu et al. 2010).
Cao et al. (2010) identified miRNA-101 (miR-101) as an
androgen responsive miRNA in prostate cancer cell lines,
with the androgen agonist R1881 stimulating miR-101
expression. They also demonstrated regulation of EZH2 by
miR-101. As mentioned earlier, EZH2 is overexpressed in
prostate cancer and, therefore, acts as an oncogene. miR-101
was found to inhibit endogenous EZH2 in PC3, DU145 and
LNCaP prostate cancer cell lines and decrease invasion and
migration of DU145 and LNCaP cells, respectively. These
findings are in keeping with another study which analysed
miR-101 expression in human prostate tumour samples and
found that miR-101 expression decreases during cancer
progression, correlating with the increase in EZH2 expression
(V arambally et al. 2008). Therefore, these studies strongly
support the notion that miR-101 functions as a tumour
suppressor by targeting EZH2.
Whilst some miRNAs are clearly regulated by andro-
gens, recently, a study identified a number of miRNAs
which target the 3′UTR of the AR mRNA and thus,
regulate AR levels (Ostling et al. 2011). The study screened
1,129 miRNAs in a panel of prostate cancer cell lines
quantifying changes in AR levels using protein lysate
microarrays. The assays identified 13 miRNAs that inhibit
AR expression. Further analysis on 47 clinical prostate
tumour samples confirmed a negative correlation between
expression of two of these, miR-34a and miR-34c and AR
expression levels. miR-34a was also found to positively
correlate with expression of the tumour suppressor p53,
which inhibits expression of genes involved in cell cycle
and apoptosis (Fujita et al. 2008). miR-34a expression was
found to be higher in p53 positive cell lines (PrEC and
LNCaP) than in p53-defective cell lines (PC3 and DU145).
This study further identified the histone deacetylase SIRT1,
which had been implicated in diverse cellular processes
including apoptosis as a direct target of miR-34a. Down-
regulation of SIRT1 was observed in PC3 and DU145 cells
compared with LNCaP cells, and SIRT1 mRNA levels also
decreased in response to ectopic expression of miR-34a.
Ectopic miR-34a expression also resulted in cell cycle arrest
at G1 phase and inhibited growth of PC3 cells. In addition,
ectopicmiR-34aexpressionattenuatedchemoresistancetothe
anticancer drug camptothecin (a topoisomerase I inhibitor) by
inducing apoptosis. These data suggest that modulation of
miR-34a activity may represent a novel approach for treating
malignant prostate cancers with aberrant p53 function.
Interestingly, CD44, which has also been implicated in
prostate cancer, as noted above, has also recently been
identified as a target of miR-34a (Liu et al. 2011a). CD44
+
prostate cancer cell populations have previously been
shown to possess cancer stem cell (CSC) properties, which
includes an enhanced tumour initiating capacity, self-renewal
capabilities, and resistance to conventional anticancer thera-
peutics. Thus, CSCs have been implicated in tumour
recurrence and metastasis (Visvader and Lindeman 2008;
Patrawala et al. 2006, 2007). A comparison of 137 miRNAs
in CD44
+ versus CD44
- prostate cancer cells purified from
xenograft and primary tumours, suggest that miR-34a is
underexpressed in the CD44
+ populations. Furthermore,
overexpression of miR-34a in CD44
+ prostate cells and
CD44 knockdown in CD44
− prostate cells inhibited clono-
genic expansion, tumour regeneration, and metastasis. In a
prostate-tumour-bearing mouse model, systemically delivered
miR-34a-inhibited prostate cancer metastasis and extended
survival of tumour bearing mice. This emerging role of miR-
34a in regulating CSCs further supports the idea that miR-34a
represents a potential therapeutic target in prostate cancer.
Several miRNAs have also been identified as oncogenic
miRNAs in prostate cancer. Analysis of miR221 and miR-
222 expression in three prostate cancer cell lines (PC3,
22RV1 and LNCaP) showed that miR-221 and miR-222 are
overexpressed in the more aggressive prostate tumour line,
PC3, compared with the less aggressive cell lines, LNCaP
and 22RV1 (Galardi et al. 2007). Galardi et al. (2007),
identified p27 mRNA as a target of miR-221 and miR-222,
with overexpression of miR-221/222 resulting in p27
downregulation in LNCaP cells and increased cell prolifer-
ation. Deregulation of cyclin-dependent kinase inhibitor
p27 has been implicated in prostate cancer progression and
is a well-established marker of poor prognosis with
decreased p27 expression associated with high tumour
grade and poor prognosis of prostate cancer (Macri and
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Furthermore in the study, knockdown of miR-221 and
miR-222 increased p27 expression in PC3 cells and
reduced their clonogenicity in vitro. Following this, a study
was conducted to determine the role of miR-221and miR-222
in vivo (Mercatelli et al. 2008). LNCaP cells stably trans-
fected with miR-221 were subcutaneously injected into
SCID mice. A significant increase in growth was observed
in tumours overexpressing miR-221 correlating with a
reduction in p27 expression. Furthermore, SCID mice
injected with PC3 cells in which miR-221/222 were knocked
down, displayed significantly reduced tumour growth asso-
ciated with increased p27 expression.
There is currently intense interest in the action of
miRNAs and their important role in cancer progression is
increasingly recognised. It is clear that there are global
changes to miRNAs in prostate cancer, and a number of
these miRNAs, including those highlighted above, are
already being recognised as potential biomarkers or
therapeutic targets. However, we still have much to learn
about the mechanism of action and target selection of
miRNAs, and further research is clearly needed in order to
understand the role of these molecules in prostate and other
cancers.
Epigenetic modifications as potential prostate cancer
biomarkers
The current challenge for prostate cancer is its early
detection, as this provides the best chance of successful
treatment. Since the introduction of PSA testing, there has
been a significant increase in the diagnosis of prostate
cancer. Although PSA is the best tumour marker available
today, PSA screening has limited accuracy. Whilst a PSA
level of more than 4.0 ng/mL has predictive value for the
diagnosis of prostate cancer (Thompson et al. 2004), the
Prostate Cancer Prevention Trial conducted by Thompson
et al. (2004) showed that 15% of men with a serum PSA
value less than 4.0 ng/mL have prostate cancer, with 25%
of these men having cancer of Gleason score 7 or above.
Further, the majority of those with elevated PSA do not
have prostate cancer (Villers et al. 1997). Therefore, there is
an urgent need for more accurate biomarkers that can
identify men at high prostate cancer risk and therefore
improve current treatments.
Recently, increased understanding of the involvement of
epigenetic alterations in the early stages of cancer has led to
the investigation of epigenetic changes, particularly DNA
hypermethylation as potential biomarkers. DNA hypermethy-
lationisarelativelystablemodificationandhasthereforebeen
investigated as a potential biomarker, as reviewed in Phé et al.
(2010). Furthermore, DNA methylation can be easily
detected using highly sensitive PCR-based methods and
bisulphite sequencing. In addition, as outlined above, many
studies suggest that DNA hypermethylation is an important
mechanism leading to gene loss of function in prostate
cancer (Li et al. 2004; Whang et al. 1998;N a k a y a m ae ta l .
2003). Further, recent studies suggest that DNA hyper-
methylation is involved in an early event in carcinogenesis
(Feinberg et al. 2006) and, therefore, DNA hypermethylation
may prove to be a useful tumour biomarker.
As described earlier, GSTP1 hypermethylation is a
common occurrence in prostate cancer and has therefore
been investigated as a potential biomarker. Jeronimo et al.
(2004) examined promoter hypermethylation at GSTP1 and
several other gene promoters in 118 prostate cancer
samples, 38 paired high-grade PIN and 30 BPH, in order
to determine the sensitivity of using GSTP1 hypermethy-
lation as a biomarker to detect prostate cancer. Interestingly,
the results showed that the frequency of methylation was
different between the three groups with no GSTP1 promoter
hypermethylation observed in BPH. This suggests that
GSTP1 promoter hypermethylation is a sensitive prostate
cancer marker with the ability to distinguish between the
different stages of prostate cancer. In addition, the study
found that using a combination of GSTP1 and APC
methylation levels increased the detection rate of prostate
cancer to almost 94%. Similarly, another study of promoter
hypermethylation of GSTP1, APC and prostaglandin-
endoperoxide synthase 2 (or cyclo-oxygenase 2 (COX-2))
reported that GSTP1 methylation analysis in combination
with either or both of the other genes provided good
correlation with tumour stage and Gleason score but not
PSA levels (Bastian et al. 2007). Therefore, analysis of a
combinationofhypermethylatedgenesmayprovideincreased
sensitivity and specificity of prostate cancer detection and
therefore may have potential as a biomarker inprostate cancer
diagnosis.
In addition, a number of studies have demonstrated that
DNA methylation may be detectable in urine samples,
raising the possibility of detecting epigenetic changes using
non-invasive screening methods. Cairns et al. (2001)
demonstrated that GSTP1 hypermethylation can be detected
in voided urine using methylation-specific PCR. Whilst
GSTP1 hypermethylation was only detected in one third of
the urine samples of which it was found in matched prostate
cancer samples, it was not detected in any of the samples in
which prostate tissue was negative for GSTP1 hyper-
methylation. This demonstrates that molecular diagnosis
of prostate cancer by analysis of DNA methylation in urine
samples may be feasible. In support of this, Goessl et al.
(2001) analysed urine sediments from patients with BPH,
PIN and various stages of prostate cancer and reported
detection of GSTP1 promoter methylation with 98%
specificity and 73% sensitivity. A further study investigated
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voided urine (Roupret et al. 2007). The study involved 95
individuals with early prostate cancer and found that a four-
gene combination of GSTP1, RASSF1a, retinoic acid
receptor β2 (RARβ2) and APC was the best discriminator
of malignant compared with non-malignant samples with a
sensitivity of 86% and an accuracy of 89%. These studies,
therefore, suggest that post-prostate massage-voided urine
may be a realistic alternative as a non-invasive method of
prostate cancer screening, with multiple gene panels
providing a better discrimination of malignant from non-
malignant cells.
Another potential cancer biomarker is the cell-free
circulating DNA in serum/plasma. Recent studies have
shown that individuals with prostate cancer have higher
levels of cell-free DNA and that the DNA fragmentation
pattern from healthy individuals is different to that from
individuals with benign prostate cancer (Ellinger et al.
2008b; Jung et al. 2004; Papadopoulou et al. 2004; Altimari
et al. 2008). The cell-free circulating DNA seems to be
released from solid malignant tumours that undergo cellular
necrosis and apoptosis (Jahr et al. 2001). Allen et al. (2004)
showed that individuals with prostate cancer and PIN had
significantly higher levels of cell-free circulating DNA
compared with those with BPH. However, this increase in
cell-free DNA appears to be a common feature of cancer, as
it is also observed in breast (Huang et al. 2006), cervical
(Trejo-Becerril et al. 2003), lung (Sozzi et al. 2001) and
bladder (Ellinger et al. 2008a) cancer. Therefore, detecting
methylation of a panel of prostate cancer-specific genes in
the cell-free circulating DNA may be useful to allow a more
specific diagnosis. Cell-free DNA hypermethylation at
GSTP1 detected in individuals with prostate cancer, in a
number of studies have shown a diagnostic specificity of
nearly 100% (Jeronimo et al. 2002; Bastian et al. 2005;
Papadopoulou et al. 2004; Reibenwein et al. 2007; Chuang
et al. 2007; Altimari et al. 2008). However, detection of
methylation at a panel of prostate-cancer-specific genes
(GSTP1, TIGI, COX-2 and RPRM) increased the sensitivity
of diagnosis and the ability to predict prognosis of prostate
cancerevenfurther(Ellingeretal.2008c). Therefore, cell-free
DNA may be a promising non-invasive biomarker for
prostate cancer.
Finally, very recently miRNAs have been suggested as
potential biomarkers in prostate cancer. An expression
profile study consisting of six prostate cancer-related
miRNAs (miR-141, miR-16, miR-101, miR-34c, miR-21
and miR-125b) was conducted on human prostate samples
and prostate cell lines of both benign and malignant
tumours (Hao et al. 2011). These miRNAs were selected
on the basis of their association with prostate cancer-related
proteins, PSA, Bcl-2, COX-2, and p53. However, expression
levels of all six miRNAs were different across cell lines,
corresponding xenograft tumours and human specimens.
Interestingly, all the miRNAs showed a significantly different
expression pattern when compared between the benign cell
line, BPH1, and the tumourigenic subline, BPH1
CAFTD,w i t h
miR-21 and miR-125b highly expressed in BPH1
CAFTD,
and lower expression of miR-16, miR-34c, miR-101 and
miR-141 detected in BPH1 cells. Therefore, profiles of these
miRNAs clearly distinguished the benign BPH1 from the
tumourigenic BPH1
CAFTD cells. Analysis of human tissue
samples showed a twofold upregulation of miR-21 and miR-
141 in tumour samples compared with BPH samples,
suggesting that miR-21 and miR-141 might be a potential
biomarker useful for distinguishing tumours from benign
samples. In addition, miRNAs have been detected in human
plasma in a stable form and, thus, may be an attractive non-
invasive biomarker (Mitchell et al. 2008). A panel of six
miRNAs (miR-100, miR-125b, miR-141, miR-143, miR-205
and miR-296) were also analysed in serum samples from 25
individuals with metastatic prostate cancer and 25 healthy
individuals as controls. Of all the miRNAs examined, miR-
141 showed a significantly higher expression in individuals
diagnosed with prostate cancer compared with individuals
without prostate cancer, correlating well with the previous
study by Hao et al. (2011). Therefore, miR-141 appears to be
a potential non-invasive biomarker that can distinguish
prostate cancer from benign or healthy controls.
Pharmacological reversal of epigenetic modifications
in prostate cancer
Ashighlightedabove,changesinepigeneticmodificationsare
increasingly being associated with prostate cancer. Unlike
genetic mutations, epigenetic alterations are potentially
reversible and a range of pharmacological reagents that
reverse epigenetic modifications have been characterised in
recent years (see Fig. 1). This review highlights several of
these agents and their potential use in the treatment of
prostate cancer.
Pharmacological reversal of DNA hypermethylation
in prostate cancer
DNA methylation can be reversed by DNA methyltransferase
inhibitors (DNMTi), as indicated in Fig. 1. The azanucleo-
side, 5-azacytidine was the first DNMTi developed and was
shown to demethylate DNA in human cell lines (Jones and
Taylor 1980). This modified nucleoside is incorporated into
DNA during replication and is recognised by the DNMT
enzymes. However, the reaction is not able to be completed
and 5-azacytidine traps the DNMT enzyme on the DNA
(Santi et al. 1984). Consequently, the DNA remains
unmethylated and the DNMT enzyme is rapidly depleted
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following DNA replication. However, 5-azacytidine is a
ribose nucleoside which must be converted to a deoxyribo-
nucleoside triphosphate before incorporation into DNA, and
therefore, some of the 5-azacytidine is incorporated into
RNA, and thus, it has cellular effects unrelated to DNA
demethylation (Cihak 1974). Consequently, the analogue
5-aza-2′-deoxycytidine (decitabine) was developed, which
is directly incorporated into DNA.
There have been a plethora of studies demonstrating the
ability of the nucleoside inhibitors to re-express genes
silenced by DNA methylation in prostate cancer cell lines,
and due to space limitations only a few of these studies will
be highlighted here. In 1997, two independent studies
examined the effect of DNMTi on cyclin-dependent kinase
2a (CDKN2) gene expression (Chi et al. 1997; Jarrard et al.
1997). CDKN2 is a tumour suppressor gene which is
suggested to play an important role in prostate cancer
progression (Cairns et al. 1995). Re-expression of the
CDKN2 gene in non-expressing prostate cancer cell lines
(PC3, PPC1 and TSU-PR1) was observed following
treatment with 5-azacytidine and 5-aza-2′-deoxycytidine.
In both studies, morphological changes were observed in
the cell lines following treatment with the demethylating
agents. Further, both studies reported a decrease in growth
rate in the PC3 cell lines treated with the DNMTi.
Subsequently, Whang et al. (1998) examined the candidate
tumour suppressor gene PTEN/MMAC1. This gene is
implicated in multiple tumours, including prostate cancer.
In this study, a LuCaP-35 xenograft was explanted from an
animal, then propagated in culture and treated with 5-aza-2′-
deoxycytidine. The treatment successfully restored PTEN/
MMAC1 gene expression in the LuCAP-35 prostate cancer
xenograft cells. Additionally, given the prevalence of GSTP1
hypermethylation in prostate cancer, as discussed earlier,
demethylation of the GSTP1 gene following DNMTi treat-
ment has been studied extensively. For example, studies
conducted by Lin et al. (2001b) and Singal et al. (2001)
demonstrated rescue of GSTP1 expression in LNCaP cells
using 5-azacytidine and 5-aza-2′-deoxycytidine, respectively.
Similarly, Vidanes et al. (2002) successfully restored expres-
sion of GSTP1 in the MDA PCa 2a and MDA PCa 2b
prostate cancer cell lines by treatment with 5-azacytidine.
The effects of DNMTi have also been studied using in
vivo models of prostate cancer, including the transgenic
adenocarcinoma of the mouse prostate (TRAMP) mouse
model. TRAMP is a prostate cancer mouse model, which
closely mirrors the pathogenesis of human prostate cancer.
Zorn et al. (2007) conducted a study to determine the effect
of 5-azacytidine on pre-existing TRAMP mouse prostate
cancers and its ability to prevent androgen-independent
prostate cancer. In this study, 5-azacytidine treatment
prevented prostate enlargement and prolonged the time
taken to develop androgen-independent status. Further, a
recent study by Gravina et al. (2010) suggests 5-azacytidine
in combination with anti-androgen therapy may have
therapeutic potential in some individuals. This study, in
which cells were treated with 5-azacytidine along with the
anti-androgen bicalutamide (BCLT), was conducted using
both cell lines and an in vivo model in which PC3 and
22RV1 cells where subcutaneously injected into the flank of
CD1 nude mice. 5-Azacytidine acted synergistically with
BCLT in both cases, upregulating cell cycle proteins and
increasing the balance of pro-apoptotic compared with anti-
apoptotic proteins. In addition, treatment with 5-azacytidine
and BCLT in combination significantly repressed tumour
growth in vivo, suggesting that the combined treatment has
an anti-tumour effect. Further investigation of the in vivo
model also detected upregulation of caspases, which
suggests this effect may be mediated by the induction of
apoptosis.
5-Azacytidine and 5-aza-2′-deoxycytidine are the most
clinically advanced DNMTi and have been examined exten-
sively in clinical trials in a range of cancers, with 5-aza-2′-
deoxycytidine receiving US Food and Drug Administration
(FDA) approval for the treatment of myelodysplastic syn-
drome (Kaminskas et al. 2005). However, a small number of
clinical trials conducted in individuals diagnosed with
prostate cancer suggest these inhibitors may have more
limited use in prostate cancer. Although the in vitro studies
of nucleoside inhibitors have been successful in restoring
silenced gene expression in prostate cancer cell lines, as
described above, a phase II study of 5-aza-2′-deoxycytidine
conducted in 14 men with androgen-independent metastatic
prostate cancer had limited success with only two of the 12
individuals displaying stable disease with delayed time to
progression (Thibault et al. 1998). This study concluded that
whilst 5-aza-2′-deoxycytidine is well tolerated, it has only
moderate effects on hormone-independent prostate cancer.
Further, although these inhibitors may reverse aberrant DNA
hypermethylation, they have previously been found to have
side effects such as myelosuppression (Kantarjian et al.
2003; Schrump et al. 2006; Appleton et al. 2007;C a s h e ne t
al. 2008; Batty et al. 2010;C h u a n ge ta l .2010), tumouri-
genesis (Walker and Nettesheim 1986; Schnekenburger et al.
2011;H a m me ta l .2009) and mutagenesis (Jackson-Grusby
et al. 1997; Perry et al. 1992; Saunthararajah et al. 2003;
Lavelle et al. 2007), which may limit their usefulness as a
therapeutic drug in prostate cancer.
Non-nucleoside DNMTi have also been characterised and
their ability to reverse DNA hypermethylation examined in
prostate cancer. The non-nucleoside DNMTi procainamide
acts mainly by inhibiting DNMT1 (Lee et al. 2005).
Procainamide treatment was found to successfully reverse
GSTP1 CpG island hypermethylation and restore GSTP1
expression in LNCaP prostate cancer cells (Lin et al. 2001a).
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LNCaP prostate cancer cells were inoculated into the
subcutaneous region of the flanks of athymic mice.
Following treatment with procainamide for 2 weeks, the
xenograft tumours were excised and found to display
increased GSTP1 expression, correlating with a reduction
in GSTP1 CpG island methylation. Whilst this study
suggests that non-nucleoside DNMTi may effectively reverse
methylation-dependent gene silencing in prostate cancer
cells, a study by Chuang et al. (2005) which examined the
effectiveness of procainamide and two other non-nucleoside
demethylating agents; (−)-epigallocatechin-3-gallate and
hydralazine, compared with the nucleoside inhibitor 5-aza-
2′-deoxycytidine in a range of prostate cancer cell lines,
found that 5-aza-2′-deoxycytidine is considerably more
effective in demethylating DNA and reactivating genes
compared with the non-nucleoside inhibitors.
Whilst agents that inhibit DNA methylation are therefore
being actively investigated as potential therapeutic agents in
prostate cancer, one issue that also needs to be considered is
their potential to hypomethylate and therefore upregulate
genes involved in metastasis. As outlined above, hypomethy-
lation of a number of genes has been linked to prostate cancer
progressionandmetastasis(Shukeiretal.2006) and the effect
of DNMTi on these genes also needs to be considered.
Use of histone deacetylase inhibitors in prostate cancer
Two types of enzymes are involved in determining the
acetylation and deacetylation of the histone tails: histone
acetyltransferases and histone deacetylases (HDACs). Studies
on prostate cancer samples, cell lines and prostate cancer
mouse models have shown that HDAC activity is upregulated
in prostate cancer (Halkidou et al. 2004; Waltregny et al.
2004). HDAC complexes can be inhibited by a variety of
agents known as HDAC inhibitors (HDACi), as indicated in
Fig. 1. These fall into a number of categories, namely,
hydroxamic acids, aliphatic acids, cyclic peptides, and
benzamides. A range of these HDACi have been examined
for their potential use in prostate cancer, and the most
extensively examined and those with the most promising
therapeutic potential will be highlighted here.
Trichostatin A (TSA) was one of the first natural
compounds found to be a potent HDACi. A study by
Huang et al. (1999) treated the prostate cancer cell line PC3
with the HDACi sodium butyrate and TSA. They found
that PC3 cells undergo differentiation and apoptosis
following sodium butyrate treatment. Another study con-
ducted by Rashid et al. (2001), also treated a range of
prostate cancer cell lines with sodium butyrate and TSA.
This study investigated whether HDACi treatment modu-
lated responses of prostate cancer cells to 1 alpha, 25-
dihydroxyvitamin D(3). 1 Alpha, 25-dihydroxyvitamin D
(3) is involved in regulating the growth and differentiation
of the prostate (Schwartz and Hulka 1990; Konety et al.
1996), but prostate cancer cells are less sensitive to this
hormone (Miller et al. 1995; Krill et al. 1999). They found
that sodium butyrate and TSA had little effect on their own at
low doses but synergized with 1 alpha, 25-dihydroxyvitamin
D(3) to inhibit the growth of the prostate cancer cell lines.
These studies suggest that TSA and sodium butyrate inhibit
prostate cancer cell growth by inducing apoptosis. However,
the anti-proliferative effects of these HDACi are likely to be
complicated as Suenaga et al. (2002), have also shown that
TSA and sodium butyrate downregulate telomerase activity
in both PC3 and LNCaP cell lines.
Suberoylanilide hydroxamic acid (SAHA; V orinostat)
was the first HDACi approved by the US FDA for the
treatment of cancer, in particular the treatment of cutaneous
T-cell lymphoma. This compound has been found to inhibit
proliferation of the prostate cancer cell lines LNCaP , DU-145
and PC3 (Lakshmikanthan et al. 2006;C h i n n a i y a ne ta l .
2005;G e d i y ae ta l .2008;K u l pe ta l .2006;M a r r o c c oe ta l .
2007; Schmudde et al. 2008). SAHA has also been tested in
animal models of prostate cancer and found to have potential
as an anti-tumour drug. SAHA was used to treat mice
transplanted with CWR22 human prostate tumours (Butler et
al. 2000). At a dose without detectable toxicity, a 97%
reduction in tumour growth was detected. These results
suggest that SAHA is relatively non-toxic and may be useful
in treating prostate cancer. As most metastatic prostate
cancer cells tend to be oxidatively stressed (Halliwell
2006), a recent study by Basu et al. (2011), using LNCaP
and PC3 prostate cancer cell lines, showed that the response
to SAHA was enhanced by combination treatment with an
anti-oxidant like vitamin E and SAHA. Qian et al. (2006)
also investigated the effect of another HDACi, panobinostat,
in a prostate cancer mouse model. A PC3 xenograft mouse
model was examined following a daily treatment with
panobinostat and this treatment was found to inhibit tumour
growth and angiogenesis.
The aliphatic acid, valproic acid (VPA) is another
HDACi that has been investigated in both in vitro and in
vivo prostate cancer models. The prostate cancer cell lines
DU-145 and PC3 were treated with VPA and their viability
and cell cycle status monitored along with expression of
cell cycle and proliferation markers (Shabbeer et al. 2007).
The anti-proliferative effect of VPA was dose and time
dependent and an effect on cell cycle arrest was observed
even 24 h after its removal. VPAwas then administered in
the drinking water of nude mice bearing xenografts of
human prostate cancer cell lines, DU-145 and PC3. In this
model, VPAwas able to induce growth arrest, cell death and
senescence. An increase in acetyl H3K9 was detected in
VP A-treated xenografts, suggesting that VP Awas functioning
as an HDACi in this model.
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romidepsin) has also been extensively examined in exper-
imental studies of prostate cancer. Lai et al. (2008)
conducted a study to determine the effects FK228 has on
prostate cancer cells in vivo. 22RV1 cells were subcutane-
ously inoculated into male non-obese diabetic-severe
combined immune-deficient mice and were either left
untreated or treated with FK228, given orally three times
a week. All the untreated mice had died at 98 days whereas,
61% of the treated mice remained alive. In addition, in
untreated mice the human prostate cancer cells metastasized
to the lung, whereas FK228-treated mice showed normal
lung morphology. These data, therefore, suggest that FK228
is efficient at suppressing prostate cancer metastases.
Recently, Zhang et al. (2007) also conducted a study to
determine whether FK228 can augment the effect of other
chemotherapeutic agents against androgen-independent
prostate cancer. They tested the combination of FK228
with docetaxel (a microtubule stabilizer and conventional
chemotherapeutic agent), 5-aza-2′-deoxycytidine (the nu-
cleoside DNMTi described above) and genistein (a protein
kinase inhibitor) on three androgen-independent prostate
cancer cell lines, PC3, DU-145 and C4-2. They found that
FK228/docetaxel had greater cytotoxic effects than the
other combinations. Furthermore, in vivo treatment of nude
mice with PC3 tumours with FK228/docetaxel had greater
inhibitory effects than the other compounds. Thus, FK228
augments the effect of docetaxel against androgen-
independent prostate cancer, providing a promising treatment
option.
MS-275 is an orally active synthetic benzamide deriva-
tive with HDACi activity. Qian et al. (2005) conducted a
study to evaluate the effects of combination therapy of MS-
275 with 13-cis retinoic acid to reactivate RARβ2 gene
expression in the human prostate cancer cell lines PC3 and
DU-145. Retinoids have been used in the treatment of
epithelial tumours but their use has been hindered by the
development of resistance and is associated with the
silencing of RARβ2 gene expression due to DNA
methylation and histone deacetylation. The effects of the
combination therapy to reactivate the RARβ2 gene expres-
sion was also examined in nude mice, which were injected
with PC3 cells stably transfected with a RARβ2 promoter-
luciferase gene. The combination therapy was able to
reactivate endogenous RARβ2 gene expression by acetyla-
tion of the RARβ2 promoter both in vitro and in vivo. The
combination therapy also resulted in synergistic activation
of the luciferase reporter gene both in vitro and in vivo. In
addition, combination therapy restored retinoid sensitivity
in prostate cancer cell lines and had a greater inhibitory
effect on tumour cell growth compared with treatment with
the agents by themselves. Therefore, this study suggests
that HDACi and retinoid combination therapy may be a
promising treatment option for retinoid-resistant prostate
cancer. Subsequently, Qian et al. (2007) conducted another
study to examine the biological effects of MS-275 both in
vitro (PC3, LNCaP and DU-145) and in vivo (PC3, LNCaP
and DU-145 injected mice and TRAMP mice). MS-275
significantly upregulated histone H3 acetylation and p21 (a
potent cyclin-dependent kinase inhibitor) gene expression
in the PC3, LNCaP and DU-145 cell lines. Upregulation of
p21 corresponded with growth arrest in PC3 and LNCaP
cells and MS-275 treatment induced cell death in DU-145
cells. In the in vivo models, MS-275 successfully inhibited
the growth of PC3, LNCaP and DU-145 in subcutaneous
xenografts. Tumour samples from MS-275 treated mice had
increased histone acetylation levels and increased expression
of p21. Long-term treatment of MS-275 in TRAMP mice
slowed progression of prostate carcinomas with a significant
reduction in cell proliferation. Therefore, these data strongly
suggest that MS-275 is a promising HDACi for the treatment
of prostate cancer.
Clinical trials
There have been a number of clinical trials on HDACi
conducted in individuals diagnosed with prostate cancer
either alone or in combination with other anti-cancer agents.
A phase I clinical study with oral panobinostat alone or in
combination with docetaxel in castration-resistant prostate
cancer was conducted in 16 individuals (Rathkopf et al.
2010). In this trial, a total of eight individuals were treated
with oral panobinostat alone and another eight individuals
were treated with oral panobinostat in combination with
intravenous docetaxel. All individuals treated with panobi-
nostat alone developed progressive disease. However, five
individuals treated with the combination therapy achieved a
partial response and this included an individual that had
previously progressed on docetaxel alone. A phase I trial of
the HDACi SAHA in combination with doxorubicin has also
been conducted (Munster et al. 2009). This study involved
32 individuals with a range of solid tumours, including two
with prostate cancer. Doxorubicin is a topoisomerase II
inhibitor and a commonly used chemotherapy agent for solid
tumours. The individuals with prostate cancer showed partial
responses to the treatment as determined by PSA assessment
and were found to have higher levels of histone acetylation
in their tumour tissue samples. These studies suggest that
HDACi in combination with other conventional anti-cancer
agents may have potential for the treatment of prostate
cancer.
Recently, a phase II clinical trial of FK228 was
undertaken involving individuals with progressing, meta-
static, castration-resistant prostate cancer (Molife et al.
2010). FK228 was intravenously administered to a total of
35 individuals. Two individuals achieved stable disease
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levels of more than 50%. However, 11 individuals
discontinued the treatment due to toxicity and reported side
effects such as nausea, fatigue, vomiting and anorexia.
Use of histone methylation modulators in prostate cancer
The development of inhibitors of HMTs and HDMs is less
advanced than for DNMTs and HDACs; however, there are
a number of inhibitors of these molecules that have now
been investigated in cancer models, including prostate
cancer. Recently, a carbocyclic adenosine analogue, 3-
dezaneplanocin-A (DZNep), was found to inhibit EZH2
HMTactivity and, thus, inhibit H3K27 methylation (Tan et
al. 2007; Chase and Cross 2011). Although subsequent
studies suggest that this agent is a global HMT inhibitor
rather than a specific EZH2 inhibitor (Miranda et al. 2009),
several studies had demonstrated anti-tumourigenic activi-
ties in prostate cancer models. Crea et al. (2011) investi-
gated the effects of DZNep on prostate CSCs. Treatment of
two prostate cancer cell lines; the less aggressive LNCaP
and the tumourigenic DU145 with 1 μM DZNep inhibited
EZH2 expression and reduced H3K27 methylation by 33%.
Treatment of both cell lines with DZNep also inhibited
formation of spheres, which are associated with CSC
formation, by 95%. In addition, DZNep decreased the
CSC enriched cell population (CD44
+/24
−) in LNCaP cells
containing 0.1% CSC fraction and caused apoptosis in
DU145 cells which are almost 100% CD44
+ and more stem
cell like. The effect of DZNep on in vivo tumour growth
was examined by pre-treatment of LNCaP and Du145 with
DZNep and then injection of these cells into NOD/SCID
mice. In LNCaP , DZNep significantly reduced tumour
formation in NOD/SCID mice but this effect was not
observed in DU145. This suggests that DZNep is more
effective in the early stage of prostate cancer by preventing
prostate cancer metastasis rather than in the advanced stage
of prostate cancer.
As noted above the HDM, LSD1 is upregulated in
high-risk tumours and, therefore, inhibition of LSD1 is
likely to be an attractive therapeutic target (Kahl et al.
2006). Since LSD1 is an amine oxidase, its activity can be
inhibited by monoamine oxidase inhibitors, such as
pargyline (Metzger et al. 2005). Pargyline was found to
block demethylation of H3K9me1 and H3K9me2 during
androgen-induced transcription in LNCaP cells. In addition,
Kahl et al. (2006) showed that pargyline treatment of the
LNCaP prostate cancer cell line conferred dose-dependent
growth inhibition.
Currently, there are no studies of pargyline, DZNep or
other modulators of histone methylation in clinical trials.
However, modulation of histone methylation represents a
promising therapeutic target, and therefore further investi-
gation of these, or other inhibitors, as they become
available is clearly warranted.
Conclusions
Earlyandaccuratediagnosisofprostatecancerisessential,and
available studies suggest that gene-specific DNA methylation
analysis may prove to beuseful as a prostate cancer biomarker.
Hypermethylation of the GSTP1 promoter, particularly in
combination with other genes implicated in tumourigenesis, is
proving to be a highly specific and sensitive measure of
prostate cancer. Hypermethylation of particular genes also
appears to be an early event in prostate cancer development.
Further studies are, therefore, required to identify panels of
genes that are aberrantly methylated in prostate cancer and
may be useful in early detection of the disease.
In prostate cancer, as in other cancers, epigenetic
changes are proving to be as common and important in
tumour development and progression as genetic changes.
Given the potential to reverse aberrant epigenetic modifi-
cations, and the promising results that have been reported
for some inhibitors of epigenetic modifiers in prostate
cancer animal models and clinical trials, further investiga-
tion of the mechanisms of action of these agents on prostate
cancer cells is warranted. As recent studies suggest, these
agents are most likely to be of use in the clinic when used
in combination with conventional therapies, and further
studies are therefore required to investigate their action in
combination with other chemotherapeutic agents.
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